Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: The value of diagnostic predictors of prostate cancer

BJU International

Volumn 86, Issue 1, 2000, Pages 58-64

  Unal, D ^a   Sedelaar, J P M ^b   Aarnink, R G ^c   Van Leenders, G J L H ^c   Wijkstra, H ^c   Debruyne, F M J ^c   De la Rosette, J J M C H ^c  

^a HARRAN UNIVERSITY   (Turkey)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

Contrast enhanced; Diagnosis; Power Doppler; Prostate pathology; Three dimensional ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SHU 508;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOPPLER FLOWMETRY; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; THREE DIMENSIONAL IMAGING; TRANSURETHRAL MICROWAVE THERMOTHERAPY;

EID: 0033946973     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00719.x     Document Type: Article

References (25)

1. 1 Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997; 47: 273-87
2. 2 Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64
3. 3 Djavan B, Zlotta A, Kratzik C et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5-4.0 ng/mL. Urology 1999; 54: 517-22
4. 4 Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306
5. 5 Aarnink RG, Beerlage HP, De La Rosette JJ, Debruyne FM, Wijkstra H. Transrectal ultrasound of the prostate: innovations and future applications. J Urol 1998; 159: 1568-79
6. 6 Cornud F, Belin X, Piron D et al. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. Urology 1997; 49: 709-15
7. 7 Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993; 186: 509-13
8. 8 Bogers HA, Sedelaar JP, Beerlage HP et al. Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Urology 1999; 54: 97-104
9. 9 Giesen RJ, Huynen AL, Aarnink RG et al. Computer analysis of transrectal ultrasound images of the prostate for the detection of carcinoma: a prospective study in radical prostatectomy specimens. J Urol 1995; 154: 1397-400
10. 10 Hamper UM, Trapanotto V, De Jong MR, Sheth S, Caskey CI. Three-dimensional US of the prostate: early experience. Radiology 1999; 212: 719-23
11. 11 Aarnink RG, Beerlage HP, de la Rosette JJ, Debruyne FM, Wijkstra H. Contrast angiosonography: a technology to improve Doppler ultrasound examinations of the prostate. Eur Urol 1999; 35: 9-20
12. 12 Lavoipierre AM, Snow RM, Frydenberg M et al. Prostatic cancer: role of color Doppler imaging in transrectal sonography. Am J Roentgenol 1998; 171: 205-10
13. 13 Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995; 195: 86-90
14. 14 Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS, Power Doppler US. a potentially useful alternative to mean frequency-based color Doppler US. Radiology 1994; 190: 853-6
15. 15 Cho JY, Kim SH, Lee SE. Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. J Ultrasound Med 1998; 17: 283-7
16. 16 Okihara K, Watanabe H, Kojima M. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999; 25: 89-94
17. 17 Ragde H, Kenny GM, Murphy GP, Landin K. Transrectal ultrasound microbubble contrast angiography of the prostate. Prostate 1997; 32: 279-83
18. 18 Downey DB, Fenster A. Three-dimensional power Doppler detection of prostatic cancer. Am J Roentgenol 1995; 165: 741
19. 19 Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. The essentials. 3rd edn. Chapt. 3. Baltimore: MA: Williams & Wilkins, 1996: 43-74
20. 20 Spencer JA, Alexander AA, Gomella L, Matteucci T, Goldberg BB. Clinical and US findings in prostate cancer: patients with normal prostate-specific antigen levels. Radiology 1993; 189: 389-93
21. 21 Tarcan T, Ozveri H, Biren T, Turkeri L, Akdas A. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Int J Urol 1997; 4: 362-7
22. 22 Kelly IM, Lees WR, Rickards D. Prostate cancer and the role of color Doppler US. Radiology 1993; 189: 153-6
23. 23 Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5-7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-9
24. 24 Gettman MT, Pacelli A, Slezak J et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999; 54: 479-85
25. 25 Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83: 535-55